X-linked Hypophosphatemia Clinical Trial
Official title:
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
This is phase 3b open-label, international, multicenter study to continue to monitor the long-term safety and efficacy of burosumab in adult patients with XLH that participated in previous clinical trials with burosumab (UX023-CL303 / UX023-CL304).
XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. XLH is the most common inherited form of rickets and the most common inherited defect in renal tubular phosphate transport. XLH is transmitted as an X-linked dominant disorder. Mutations resulting in the loss of function of PHEX form the genetic basis for XLH. More than 300 different PHEX gene mutations have been identified in patients with XLH (PHEXdb); however, few definitive correlations have been observed between specific mutations and phenotypic severity. Patients with XLH have hypophosphatemia due to excessive serum FGF23 levels. FGF23 reduces serum phosphorus levels by two distinct mechanisms of action. The primary mechanism is to inhibit phosphate reabsorption in the proximal tubule of the kidney. The secondary mechanism is to decrease phosphate absorption by the small intestine through the inhibition of 1,25(OH)2D production in the kidney. Burosumab has the potential to block or reduce FGF23 action and improve phosphate homeostasis in XLH patients. Burosumab binds the amino-terminal domain of FGF23 that interacts with the FGF-binding portion of the combination FGFR1/Klotho receptor, preventing FGF23 from binding to and signaling from its receptor. Both intact and fragmented FGF23 polypeptides are immunoprecipitated with burosumab. By inhibiting FGF23, burosumab restores tubular reabsorption of phosphate (as measured by the ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate [TmP/GFR]) from the kidney and increases the production of 1,25(OH)2D that also enhances intestinal absorption of phosphate. The dual action on kidney reabsorption and intestinal absorption improves serum phosphorus levels, which is expected to improve bone mineralization and reduce the diverse bone and non-bone manifestations associated with hypophosphatemia in XLH patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915705 -
Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
|
Phase 3 | |
Recruiting |
NCT03879915 -
Dental Implants in Patients With X-linked Hypophosphatemia
|
||
Active, not recruiting |
NCT03193476 -
Registry for Patients With X-Linked Hypophosphatemia
|
||
Completed |
NCT02526160 -
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
|
Phase 3 | |
Completed |
NCT05181839 -
A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
|
||
Completed |
NCT04146935 -
Examining the Effect of Burosumab on Muscle Function
|
Phase 4 | |
Completed |
NCT02750618 -
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
|
Phase 2 | |
Active, not recruiting |
NCT03745521 -
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
|
||
Recruiting |
NCT03748966 -
Calcitriol Monotherapy for X-Linked Hypophosphatemia
|
Early Phase 1 | |
Recruiting |
NCT04419363 -
Burosumab in Children and Adolescents With X-linked Hypophosphatemia
|
Phase 4 | |
Completed |
NCT02163577 -
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
|
Phase 2 | |
Active, not recruiting |
NCT03651505 -
X-linked Hypophosphatemia Disease Monitoring Program
|
||
Completed |
NCT06067932 -
Foot Disorders in X-linked Hypophosphatemia
|
||
Completed |
NCT04695860 -
Anti-FGF23 (Burosumab) in Adult Patients With XLH
|
Phase 3 | |
Completed |
NCT02312687 -
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
|
Phase 2 | |
Completed |
NCT03596554 -
X-linked Hypophosphatemia and FGF21
|
||
Recruiting |
NCT03820518 -
Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia
|
Phase 4 | |
Completed |
NCT01571596 -
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
|
Phase 1/Phase 2 | |
Completed |
NCT04273490 -
Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls
|
||
Completed |
NCT03489993 -
FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
|